Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03843125
Registration number
NCT03843125
Ethics application status
Date submitted
14/02/2019
Date registered
15/02/2019
Titles & IDs
Public title
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
Query!
Scientific title
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Query!
Secondary ID [1]
0
0
I4V-MC-JAIM
Query!
Secondary ID [2]
0
0
16832
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SLE-BRAVE-X
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Systemic Lupus Erythematosus
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Baricitinib
Treatment: Drugs - Placebo
Experimental: 2 mg Baricitinib - Participants received one 2 mg Baricitinib tablet and one placebo tablet matching 4 mg Baricitinib administered orally every day (QD).
Experimental: 4 mg Baricitinib - Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD.
Experimental: Placebo to 2 mg Baricitinib - Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 2 mg Baricitinib administered orally QD.
Experimental: Placebo to 4 mg Baricitinib - Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 4 mg Baricitinib administered orally QD.
Treatment: Drugs: Baricitinib
Administered orally.
Treatment: Drugs: Placebo
Administered orally.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Query!
Assessment method [1]
0
0
Percentage of participants with TEAEs. A treatment-emergent AE (TEAE) is defined as an event that first occurred or worsened in severity after the first dose of study treatment in Study JAIM and on or prior to the last visit date during the analysis period. The analysis period is defined as the treatment period plus up to 30 days off-drug follow-up time.
A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Query!
Timepoint [1]
0
0
Week 134
Query!
Primary outcome [2]
0
0
Percentage of Participants With Adverse Events of Special Interest (AESIs)
Query!
Assessment method [2]
0
0
Percentage of Participants with AESIs. AESI consisted of infections, positively adjudicated arterial thromboembolic events (ATE), positively adjudicated venous thromboembolic events (VTE), positively adjudicated major adverse cardiovascular events (MACE), other positively adjudicated cardiovascular events, death, anaphylactic reactions, hypersensitivity, angioedema, and malignancies.
Query!
Timepoint [2]
0
0
Week 134
Query!
Primary outcome [3]
0
0
Percentage of Participants With Serious Adverse Events (SAEs)
Query!
Assessment method [3]
0
0
Percentage of participants with SAEs. An SAE is any AE from this study that results in one of the following outcomes: Death; Initial or prolonged inpatient hospitalization; A life-threatening experience (that is, immediate risk of dying); Persistent or significant disability/incapacity; Congenital anomaly/birth defect; Important medical events that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above.
A summary of all SAE's, regardless of causality, is located in the Reported Adverse Events section.
Query!
Timepoint [3]
0
0
Week 134
Query!
Primary outcome [4]
0
0
Percentage of Participants With Temporary Investigational Product Interruptions
Query!
Assessment method [4]
0
0
Percentage of participants with temporary investigational product interruptions.
Query!
Timepoint [4]
0
0
Week 134
Query!
Primary outcome [5]
0
0
Percentage of Participants With Permanent Investigational Product Discontinuations
Query!
Assessment method [5]
0
0
Percentage of participants with permanent investigational product discontinuations.
Query!
Timepoint [5]
0
0
Week 134
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response
Query!
Assessment method [1]
0
0
SRI-4 response defined as 1)greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of \>=0.3 from baseline on a 0-3 visual analogue scale).
SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assesses disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).
Query!
Timepoint [1]
0
0
Week 134
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)
Query!
Assessment method [2]
0
0
Percentage of participants achieving a LLDAS. The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K \<=4, with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where "no activity" is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the "new feature" is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), \<=1; (4) current prednisolone (or equivalent) dose \<=7.5 mg daily.
Query!
Timepoint [2]
0
0
Week 48
Query!
Secondary outcome [3]
0
0
Change From Baseline in Prednisone Dose
Query!
Assessment method [3]
0
0
Change from baseline in prednisone dose.
Query!
Timepoint [3]
0
0
Baseline through Week 48
Query!
Secondary outcome [4]
0
0
Annualized Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index Flare Rate
Query!
Assessment method [4]
0
0
The SELENA-SLEDAI tool is a cumulative and weighted index used to assess disease activity across 24 different disease descriptors in patients with lupus. A patient's SELENA-SLEDAI total score is the sum of all marked lupus related descriptors (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, leukopenia). A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity. The annualized flare rate is calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25.
Query!
Timepoint [4]
0
0
Baseline through Week 48
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score =10 at Baseline With =50% Reduction in CLASI Total Activity Score
Query!
Assessment method [5]
0
0
The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations.
Query!
Timepoint [5]
0
0
Week 48
Query!
Secondary outcome [6]
0
0
Change From Baseline in Tender Joint Count
Query!
Assessment method [6]
0
0
The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
Query!
Timepoint [6]
0
0
Baseline through Week 48
Query!
Secondary outcome [7]
0
0
Change From Baseline in Swollen Joint Count
Query!
Assessment method [7]
0
0
The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
Query!
Timepoint [7]
0
0
Baseline trough Week 48
Query!
Secondary outcome [8]
0
0
Change From Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Total Score
Query!
Assessment method [8]
0
0
The SLICC/ACR damage index is a validated instrument to assess damage, defined as irreversible impairment, continuously persistent for 6 months (ascertained by clinical assessment), occurring since the onset of lupus, and it is based on a weighted scoring system. This index records damage occurring in participants with SLE regardless of cause, with demonstrated content, face, criterion, and discriminant validity. A score of 0 indicates no damage. Total maximum score is 47 and increasing score indicates increasing disease severity.
Query!
Timepoint [8]
0
0
Baseline through Week 48
Query!
Secondary outcome [9]
0
0
Change From Baseline in Worst Pain Numeric Rating Scale (NRS)
Query!
Assessment method [9]
0
0
Change from baseline in Worst Pain NRS. It is assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". Overall severity of a patient's pain is indicated by selecting the number that best describes the worst level of pain during the past 7 days.
Query!
Timepoint [9]
0
0
Baseline through Week 48
Query!
Eligibility
Key inclusion criteria
* Have completed the final treatment study visit of an originating study, such as study JAHZ (NCT03616912) or Study JAIA (NCT03616964).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/09/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1147
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Optimus Clinical Research - Botany
Query!
Recruitment hospital [2]
0
0
The Rheumatology Research Unit Sunshine Coast - Maroochydore
Query!
Recruitment hospital [3]
0
0
Emeritus Research - Camberwell
Query!
Recruitment hospital [4]
0
0
St. Vincent's Hospital - Fitzroy
Query!
Recruitment postcode(s) [1]
0
0
2019 - Botany
Query!
Recruitment postcode(s) [2]
0
0
4558 - Maroochydore
Query!
Recruitment postcode(s) [3]
0
0
3124 - Camberwell
Query!
Recruitment postcode(s) [4]
0
0
3065 - Fitzroy
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Montana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Nevada
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Mexico
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Ohio
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Oklahoma
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Pennsylvania
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
South Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Tennessee
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Virginia
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Wisconsin
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Buenos Aires
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Ciudad Autónoma De Buenos Aire
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Santa Fe
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Mendoza
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Tucumán
Query!
Country [29]
0
0
Austria
Query!
State/province [29]
0
0
Oberösterreich
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Graz
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Vlaams Brabant
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Brussels
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Bahia
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
MG
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
Paraná
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Rio Grande Do Sul
Query!
Country [37]
0
0
Brazil
Query!
State/province [37]
0
0
SP
Query!
Country [38]
0
0
Brazil
Query!
State/province [38]
0
0
Cuiaba
Query!
Country [39]
0
0
Chile
Query!
State/province [39]
0
0
Los Ríos
Query!
Country [40]
0
0
Chile
Query!
State/province [40]
0
0
Región Metropolitana De Santia
Query!
Country [41]
0
0
Chile
Query!
State/province [41]
0
0
Osorno
Query!
Country [42]
0
0
Chile
Query!
State/province [42]
0
0
Santiago
Query!
Country [43]
0
0
Chile
Query!
State/province [43]
0
0
Vina del Mar
Query!
Country [44]
0
0
China
Query!
State/province [44]
0
0
Guangdong
Query!
Country [45]
0
0
China
Query!
State/province [45]
0
0
Heilongjiang
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Hubei
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Jiangsu
Query!
Country [48]
0
0
China
Query!
State/province [48]
0
0
Jiangxi
Query!
Country [49]
0
0
China
Query!
State/province [49]
0
0
Jilin
Query!
Country [50]
0
0
China
Query!
State/province [50]
0
0
Shanghai
Query!
Country [51]
0
0
China
Query!
State/province [51]
0
0
Tianjin
Query!
Country [52]
0
0
China
Query!
State/province [52]
0
0
Xinjiang
Query!
Country [53]
0
0
China
Query!
State/province [53]
0
0
Zhejiang
Query!
Country [54]
0
0
China
Query!
State/province [54]
0
0
Beijing
Query!
Country [55]
0
0
China
Query!
State/province [55]
0
0
Shenyang
Query!
Country [56]
0
0
China
Query!
State/province [56]
0
0
Suzhou Shi
Query!
Country [57]
0
0
China
Query!
State/province [57]
0
0
Zhengzhou
Query!
Country [58]
0
0
Colombia
Query!
State/province [58]
0
0
Antioquia
Query!
Country [59]
0
0
Colombia
Query!
State/province [59]
0
0
Atlantico
Query!
Country [60]
0
0
Colombia
Query!
State/province [60]
0
0
Atlántico
Query!
Country [61]
0
0
Colombia
Query!
State/province [61]
0
0
Cundinamarca
Query!
Country [62]
0
0
Colombia
Query!
State/province [62]
0
0
Santander
Query!
Country [63]
0
0
Colombia
Query!
State/province [63]
0
0
Valle Del Cauca
Query!
Country [64]
0
0
Colombia
Query!
State/province [64]
0
0
Chia
Query!
Country [65]
0
0
Croatia
Query!
State/province [65]
0
0
Rijeka
Query!
Country [66]
0
0
Croatia
Query!
State/province [66]
0
0
Split
Query!
Country [67]
0
0
Czechia
Query!
State/province [67]
0
0
Praha, Hlavní Mešto
Query!
Country [68]
0
0
Czechia
Query!
State/province [68]
0
0
Brno
Query!
Country [69]
0
0
Czechia
Query!
State/province [69]
0
0
Olomouc
Query!
Country [70]
0
0
Czechia
Query!
State/province [70]
0
0
Pardubice
Query!
Country [71]
0
0
Czechia
Query!
State/province [71]
0
0
Praha 2
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Finistère
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Bordeaux
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
Lille Cedex
Query!
Country [75]
0
0
France
Query!
State/province [75]
0
0
Marseille
Query!
Country [76]
0
0
France
Query!
State/province [76]
0
0
Strasbourg
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Baden-Württemberg
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Bayern
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Rheinland-Pfalz
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Sachsen
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Berlin
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Köln
Query!
Country [83]
0
0
Greece
Query!
State/province [83]
0
0
Attiki
Query!
Country [84]
0
0
Greece
Query!
State/province [84]
0
0
Irakleío
Query!
Country [85]
0
0
Greece
Query!
State/province [85]
0
0
Larissa
Query!
Country [86]
0
0
Greece
Query!
State/province [86]
0
0
Thessaloniki
Query!
Country [87]
0
0
Hungary
Query!
State/province [87]
0
0
Békés
Query!
Country [88]
0
0
Hungary
Query!
State/province [88]
0
0
Veszprém City
Query!
Country [89]
0
0
Hungary
Query!
State/province [89]
0
0
Budapest
Query!
Country [90]
0
0
Hungary
Query!
State/province [90]
0
0
Debrecen
Query!
Country [91]
0
0
Hungary
Query!
State/province [91]
0
0
Pecs
Query!
Country [92]
0
0
Hungary
Query!
State/province [92]
0
0
Szeged
Query!
Country [93]
0
0
Hungary
Query!
State/province [93]
0
0
Székesfehérvár
Query!
Country [94]
0
0
India
Query!
State/province [94]
0
0
Gujarat
Query!
Country [95]
0
0
India
Query!
State/province [95]
0
0
Karnataka
Query!
Country [96]
0
0
India
Query!
State/province [96]
0
0
Maharashtra
Query!
Country [97]
0
0
India
Query!
State/province [97]
0
0
Rajasthan
Query!
Country [98]
0
0
India
Query!
State/province [98]
0
0
Telengana
Query!
Country [99]
0
0
Israel
Query!
State/province [99]
0
0
Kfar Saba
Query!
Country [100]
0
0
Israel
Query!
State/province [100]
0
0
Ramat Gan
Query!
Country [101]
0
0
Israel
Query!
State/province [101]
0
0
?eifa
Query!
Country [102]
0
0
Italy
Query!
State/province [102]
0
0
Milano
Query!
Country [103]
0
0
Italy
Query!
State/province [103]
0
0
Pisa
Query!
Country [104]
0
0
Italy
Query!
State/province [104]
0
0
Roma
Query!
Country [105]
0
0
Italy
Query!
State/province [105]
0
0
Udine
Query!
Country [106]
0
0
Japan
Query!
State/province [106]
0
0
Fukuoka
Query!
Country [107]
0
0
Japan
Query!
State/province [107]
0
0
Hokkaido
Query!
Country [108]
0
0
Japan
Query!
State/province [108]
0
0
Hyogo
Query!
Country [109]
0
0
Japan
Query!
State/province [109]
0
0
Kagawa
Query!
Country [110]
0
0
Japan
Query!
State/province [110]
0
0
Miyagi
Query!
Country [111]
0
0
Japan
Query!
State/province [111]
0
0
Okinawa
Query!
Country [112]
0
0
Japan
Query!
State/province [112]
0
0
Shizuoka
Query!
Country [113]
0
0
Japan
Query!
State/province [113]
0
0
Tokyo
Query!
Country [114]
0
0
Japan
Query!
State/province [114]
0
0
Hiroshima
Query!
Country [115]
0
0
Korea, Republic of
Query!
State/province [115]
0
0
Gyeonggi-do
Query!
Country [116]
0
0
Korea, Republic of
Query!
State/province [116]
0
0
Korea
Query!
Country [117]
0
0
Mexico
Query!
State/province [117]
0
0
Coahuila
Query!
Country [118]
0
0
Mexico
Query!
State/province [118]
0
0
Distrito Federal
Query!
Country [119]
0
0
Mexico
Query!
State/province [119]
0
0
Guanajuato
Query!
Country [120]
0
0
Mexico
Query!
State/province [120]
0
0
Jalisco
Query!
Country [121]
0
0
Mexico
Query!
State/province [121]
0
0
SLP
Query!
Country [122]
0
0
Mexico
Query!
State/province [122]
0
0
Tabasco
Query!
Country [123]
0
0
Mexico
Query!
State/province [123]
0
0
Yucatan
Query!
Country [124]
0
0
Mexico
Query!
State/province [124]
0
0
Yucatán
Query!
Country [125]
0
0
Mexico
Query!
State/province [125]
0
0
Ciudad De México
Query!
Country [126]
0
0
Mexico
Query!
State/province [126]
0
0
Mexico City
Query!
Country [127]
0
0
Mexico
Query!
State/province [127]
0
0
Oaxaca
Query!
Country [128]
0
0
Netherlands
Query!
State/province [128]
0
0
Fryslân
Query!
Country [129]
0
0
Netherlands
Query!
State/province [129]
0
0
Amsterdam
Query!
Country [130]
0
0
Philippines
Query!
State/province [130]
0
0
Batangas
Query!
Country [131]
0
0
Philippines
Query!
State/province [131]
0
0
Cebu
Query!
Country [132]
0
0
Philippines
Query!
State/province [132]
0
0
Davao Del Norte
Query!
Country [133]
0
0
Philippines
Query!
State/province [133]
0
0
Luzon
Query!
Country [134]
0
0
Philippines
Query!
State/province [134]
0
0
Pampanga
Query!
Country [135]
0
0
Poland
Query!
State/province [135]
0
0
Dolnoslaskie
Query!
Country [136]
0
0
Poland
Query!
State/province [136]
0
0
Kujawsko-pomorskie
Query!
Country [137]
0
0
Poland
Query!
State/province [137]
0
0
Lubuskie
Query!
Country [138]
0
0
Poland
Query!
State/province [138]
0
0
Mazowieckie
Query!
Country [139]
0
0
Poland
Query!
State/province [139]
0
0
Podlaskie
Query!
Country [140]
0
0
Poland
Query!
State/province [140]
0
0
Polska
Query!
Country [141]
0
0
Poland
Query!
State/province [141]
0
0
Warminsko-Mazurki
Query!
Country [142]
0
0
Poland
Query!
State/province [142]
0
0
Katowice
Query!
Country [143]
0
0
Poland
Query!
State/province [143]
0
0
Krakow
Query!
Country [144]
0
0
Poland
Query!
State/province [144]
0
0
Nadarzyn
Query!
Country [145]
0
0
Poland
Query!
State/province [145]
0
0
Poznan
Query!
Country [146]
0
0
Poland
Query!
State/province [146]
0
0
Szczecin
Query!
Country [147]
0
0
Poland
Query!
State/province [147]
0
0
Warszawa
Query!
Country [148]
0
0
Romania
Query!
State/province [148]
0
0
Bra?ov
Query!
Country [149]
0
0
Romania
Query!
State/province [149]
0
0
Bucure?ti
Query!
Country [150]
0
0
Romania
Query!
State/province [150]
0
0
Cluj
Query!
Country [151]
0
0
Romania
Query!
State/province [151]
0
0
Dolj
Query!
Country [152]
0
0
Romania
Query!
State/province [152]
0
0
Bucharest
Query!
Country [153]
0
0
Romania
Query!
State/province [153]
0
0
Bucuresti
Query!
Country [154]
0
0
Russian Federation
Query!
State/province [154]
0
0
Moskva
Query!
Country [155]
0
0
Russian Federation
Query!
State/province [155]
0
0
Saint Petersburg
Query!
Country [156]
0
0
Russian Federation
Query!
State/province [156]
0
0
Chelyabinsk
Query!
Country [157]
0
0
Russian Federation
Query!
State/province [157]
0
0
Kazan
Query!
Country [158]
0
0
Russian Federation
Query!
State/province [158]
0
0
Moscow
Query!
Country [159]
0
0
Russian Federation
Query!
State/province [159]
0
0
Novosibirsk
Query!
Country [160]
0
0
Russian Federation
Query!
State/province [160]
0
0
Omsk
Query!
Country [161]
0
0
Russian Federation
Query!
State/province [161]
0
0
Orenburg
Query!
Country [162]
0
0
Russian Federation
Query!
State/province [162]
0
0
Rursk
Query!
Country [163]
0
0
Russian Federation
Query!
State/province [163]
0
0
Ryazan
Query!
Country [164]
0
0
Russian Federation
Query!
State/province [164]
0
0
Smolensk
Query!
Country [165]
0
0
Russian Federation
Query!
State/province [165]
0
0
Ufa
Query!
Country [166]
0
0
Russian Federation
Query!
State/province [166]
0
0
Zonova
Query!
Country [167]
0
0
Serbia
Query!
State/province [167]
0
0
Belgrade
Query!
Country [168]
0
0
Serbia
Query!
State/province [168]
0
0
Niska Banja
Query!
Country [169]
0
0
Serbia
Query!
State/province [169]
0
0
Novi Sad
Query!
Country [170]
0
0
South Africa
Query!
State/province [170]
0
0
Durban
Query!
Country [171]
0
0
South Africa
Query!
State/province [171]
0
0
Gauteng
Query!
Country [172]
0
0
South Africa
Query!
State/province [172]
0
0
Western Cape
Query!
Country [173]
0
0
South Africa
Query!
State/province [173]
0
0
Pretoria
Query!
Country [174]
0
0
Spain
Query!
State/province [174]
0
0
Alicante
Query!
Country [175]
0
0
Spain
Query!
State/province [175]
0
0
Barcelona [Barcelona]
Query!
Country [176]
0
0
Spain
Query!
State/province [176]
0
0
Barcelona
Query!
Country [177]
0
0
Spain
Query!
State/province [177]
0
0
Madrid
Query!
Country [178]
0
0
Spain
Query!
State/province [178]
0
0
Pontevedra
Query!
Country [179]
0
0
Spain
Query!
State/province [179]
0
0
Sevilla
Query!
Country [180]
0
0
Switzerland
Query!
State/province [180]
0
0
Sankt Gallen
Query!
Country [181]
0
0
Taiwan
Query!
State/province [181]
0
0
Dalin Township
Query!
Country [182]
0
0
Taiwan
Query!
State/province [182]
0
0
Kaohsiung
Query!
Country [183]
0
0
Taiwan
Query!
State/province [183]
0
0
Taichung
Query!
Country [184]
0
0
Taiwan
Query!
State/province [184]
0
0
Tainan City
Query!
Country [185]
0
0
Taiwan
Query!
State/province [185]
0
0
Taipei
Query!
Country [186]
0
0
Taiwan
Query!
State/province [186]
0
0
Taoyuan City
Query!
Country [187]
0
0
United Kingdom
Query!
State/province [187]
0
0
Kent
Query!
Country [188]
0
0
United Kingdom
Query!
State/province [188]
0
0
London
Query!
Country [189]
0
0
United Kingdom
Query!
State/province [189]
0
0
Surrey
Query!
Country [190]
0
0
United Kingdom
Query!
State/province [190]
0
0
Doncaster
Query!
Country [191]
0
0
United Kingdom
Query!
State/province [191]
0
0
Leeds
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Incyte Corporation
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).
Query!
Trial website
https://clinicaltrials.gov/study/NCT03843125
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Query!
Available to whom?
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://vivli.org/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/25/NCT03843125/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/25/NCT03843125/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT03843125